Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CLL gets to MRD with combo therapy

Wierda WG et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7502.

Key clinical point: Ibrutinib plus venetoclax produced a high rate of undetectable minimal residual disease.

Major finding: Of 14 patients, 12 (86%) who completed 12 cycles of treatment had undetectable bone marrow MRD.

Study details: Early results of the phase 2 CAPTIVATE trial including 164 patients younger than 70 years of age with previously untreated CLL.

Disclosures: The study was sponsored by Pharmacyclics, an Abbvie company. Dr. Wierda reported consulting and research funding from Pharmacyclics, AbbVie, and several other companies.

Source: Wierda WG et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7502.

Read the article.

Citation:

Wierda WG et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7502.

This Week's Must Reads

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018